524-36-7 Usage
Description
Pyridoxamine dihydrochloride is a salt of pyridoxamine, which belongs to the family of vitamin B6 compounds. Pyridoxamine occurs naturally in animal-based food products. Its deficiency in humans potentially causes sideroblastic anemia, weakness, insomnia, and neurological disorders. It has been reported to have been effective against diabetic nephropathy.Use in mammalian cell culture as an alternative to pyridoxine or pyridoxal. Vitamin B6 is a required component of cell culture media. Historically, media have been supplemented with vitamin B6 in the aldehyde form, pyridoxal. While this is a biologically active form of vitamin B6, it is unstable in liquid media. When cells are able to utilize either pyridoxine and/or pyridoxamine, they are preferred supplement versus pyridoxal. A number of classical media are now offered with a choice between pyridoxal and pyridoxine as the vitamin A source.https://www.sigmaaldrich.com/US/en/product/sial/p9380?context=product
Chemical Properties
White crystalline powder
Uses
Different sources of media describe the Uses of 524-36-7 differently. You can refer to the following data:
1. Pyridoxamine dihydrochloride blocks pathogenic oxidative pathways in the progression of diabetic nephropathy.Pyridoxamine dihydrochloride, a derivative of vitaminB6 and potent inhibitor of AGE formation has been shown slowDKD progression, but only in patients with relatively preservedkidney function (i.e., baseline SCr 1.3 to 1.9 mg/dL).Pyridoxamine dihydrochloride (Pyridorin, NephroGenex) inhibits formation of advanced glycation end products and scavenges reactive oxygen species and toxic carbonyls. Whether these effects translate into kidney protection is unknown, although a year-long study of the effects of pyridoxamine dihydrochlo-ride in patients with type 2 diabetes and proteinuria failed to show a difference in kidney function decline with pyri-doxamine dihydrochloride in daily doses of 300 or 600 mg versus placebo treatment.
2. Pyridoxamine Dihydrochloride (cas# 524-36-7) is a compound useful in organic synthesis.
Definition
ChEBI: A hydrochloride obtained by combining pyridoxamine with two molar equivalents of hydrochloric acid. Used for treatment of diabetic nephropathy.
Preparation
The invention relates to a preparation method of pyridoxamine dihydrochloride, belonging to the technical field of the preparation of water soluble vitamins. The preparation method comprises the following steps: preparing pyridoxal oxime: taking pyridoxine hydrochloride as initial raw material and water as a reaction medium, adding activated manganese dioxide and concentrated sulfuric acid to generate pyridoxal by the reaction, and then reacting with anhydrous sodium acetate and hydroxylamine hydrochloride to obtain pyridoxal oxime; preparing pyridoxamine dihydrochloride: firstly enabling pyridoxal oxime to react with acetic acid and zinc to obtain acetic acid solution containing pyridoxamine, then decompressing the solution and reclaiming the acetic acid to obtain slurry concentrate, decompressing and reclaiming the acetic acid again to obtain pyridoxamine water solution, regulating the pH value to be alkaline so as to separate pyridoxamine out, adding water and hydrochloric acid after vacuum filteration, decoloring and filtering to obtain filtrate, decompressing and concentrating the filtrate until white solids are separated out, adding solvent and stirring, and finally crystallizing at the lower temperature, filtering and drying to obtain the pyridoxamine dihydrochloride. The invention has the advantages that the prepared pyridoxamine dihydrochloride has high total mol yield and purity, and the preparation method is reduced.https://patents.google.com/patent/CN101628892A/en
Purification Methods
The amine salt is crystallised from hot MeOH. The free base crystallises from EtOH with m 193-193.5o [Harris et al. J Biol Chem 154 315 1944, J Am Chem Soc 66 2088 1944]. [Beilstein 22 IV 6064, 22/12 V 324.]
Check Digit Verification of cas no
The CAS Registry Mumber 524-36-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,2 and 4 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 524-36:
(5*5)+(4*2)+(3*4)+(2*3)+(1*6)=57
57 % 10 = 7
So 524-36-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H12N2O2.2ClH/c1-5-8(12)7(2-9)6(4-11)3-10-5;;/h3,11-12H,2,4,9H2,1H3;2*1H
524-36-7Relevant articles and documents
Fabrication of ω-Transaminase@Metal-Organic Framework Biocomposites for Efficiently Synthesizing Benzylamines and Pyridylmethylamines
Chen, Lina,Ding, Yingying,Jiao, Qingcai,Liu, Junzhong,Yu, Jinhai,Zhang, Hongjuan,Zong, Weilu
, (2021/11/05)
In this study, ten ω-transaminases (ω-TAs) have been investigated to efficiently catalyze the synthesis of twenty-four functionalized benzylamines and pyridylmethylamines. We optimized the reactions, screened suitable amino donors and compared ω-transaminases activities for all aromatic aldehyde substrates. Under the optimized conditions, eighteen aromatic amines have been obtained with 60.4%–96.6% conversions and isolated only via simple extraction and recrystallization with 18.5%–81% yields on a preparative scale. Furthermore, we first immobilized the Bm-STA onto the MOFs via the physical adsorption to overcome the limitation of free enzyme and improve their industrial applications. The obtained Bm-STA/UiO-66-NH2 composites exhibited not only high enzymes loading (80.4 mg g?1) and enzyme activity recovery (95.8%), but also the better reusability, storage stability, pH stability and the tolerance to acetone and DMF.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
-
Paragraph 00103; 00104, (2013/12/03)
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carhonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease.
METHODS FOR THE SYNTHESIS OF PYRIDOXAMINE
-
Page/Page column 40-42, (2008/06/13)
The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): Formula (I), and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
